PLoS Med. 2022 Feb 3;19(2):e1003898. doi: 10.1371/journal.pmed.1003898. eCollection 2022 Feb.
ABSTRACT
Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues investigating the associations between genetically-proxied inhibition of antihypertensive drug targets and risk of common cancer subtypes using Mendelian randomization.
PMID:35113864 | DOI:10.1371/journal.pmed.1003898
